Kiora Pharmaceuticals, Inc. (KPRX)
Nasdaq: KPRX · Pharmaceutical Preparations · Encinitas, CA · filing with the SEC since 2006
Who owns Kiora Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
6
Nantahala Capital Management, LLC holds 9.99% of Common Stock, $0.01 par value, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
9
report now, of 30 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Nantahala Capital Management, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.01 par value · 9.99% in May 15, 2026
Perceptive Advisors LLC
SCHEDULE 13G · filed Aug 10, 2026 · Common Stock, $0.01 par value
Alyeska Investment Group, L.P.
SCHEDULE 13G · filed May 15, 2026 · Common Stock, $0.01 par value · 2.5% in Feb 14, 2025
ADAR1 Capital Management, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.01 per share · 9.9% in Aug 14, 2025
Rosalind Advisors, Inc.
SCHEDULE 13G/A · filed Feb 11, 2026 · Common Shares · 9.9% in Aug 13, 2025
Baselake Partners, LP
SCHEDULE 13G · filed Sep 17, 2026 · Common Stock, $0.01 par value
Orin Hirschman
SCHEDULE 13G/A · filed Jan 29, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 8.5% in Feb 10, 2025
Nantahala Capital Partners Limited Partnership
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.01 par value · reported falling below 5%, from 5.3% in Aug 14, 2025
Goldman Sachs Group Inc.
SCHEDULE 13G/A · filed Feb 12, 2025 · Common Stock, par value $0.01 per share · reported falling below 5%
What KPRX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Bayon
A company bought · acquisition · owns, named in the 10-K filed Mar 25, 2026
Jade
A company bought · acquisition · owns, named in the 10-K filed Mar 25, 2026
Panoptes
A company bought · acquisition · owns, named in the 10-K filed Mar 25, 2026
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2024 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.